Hands Of Mercy Hospice, Llc Medicare Approved Location: 111 Carter Park Dr, Suite C, Seneca, South Carolina 29678 Phone: (864) 482-7110 |
Open Arms Hospice Medicare Approved Location: 1836 West Georgia Road, Simpsonville, South Carolina 29680 Phone: (864) 233-5300 |
Heartland Hospice Services - Greenville Medicare Approved Location: 421 Se Main Street, Simpsonville, South Carolina 29681 Phone: (864) 963-0045 |
Spartanburg Regional Med Ctr Hospice Medicare Approved Location: 1530 Drayton Road, Spartanburg, South Carolina 29302 Phone: (864) 560-3900 |
Hospice Care Of South Carolina Medicare Approved Location: 110 Dillon Drive, Spartanburg, South Carolina 29307 Phone: (843) 347-2200 |
Gentiva Hospice Medicare Approved Location: 905 East Main Street Suite 2, Spartanburg, South Carolina 29302 Phone: (864) 585-6500 |
Palmetto Health Tuomey Hospice Medicare Approved Location: 500 Pinewood Road, Suite 2, Sumter, South Carolina 29154 Phone: (803) 773-4663 |
Hospice Care Of Sumter, Llc Medicare Approved Location: 112 Broad Street, Sumter, South Carolina 29150 Phone: (803) 883-5606 |
Carolina Of Sumter Medicare Approved Location: 447 North Main Street, Sumter, South Carolina 29150 Phone: (803) 467-1263 |
News Archive
Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.
Researchers from the Boston University School of Medicine have conclusively found that increased time spent leading a healthy lifestyle during midlife can keep certain diseases at bay and promote good cardiovascular health.
Patients who have had a heart attack and are treated with a high dose of a statin drug did not have significant reduction in the primary outcome of major cardiac events (coronary death, nonfatal acute heart attack, or cardiac arrest with resuscitation), but did appear to have reduced risk when certain secondary outcomes (composite end points of any coronary heart disease event) were examined, according to a study in the November 16 issue of JAMA.
Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for Endo's long-acting testosterone undecanoate injection, AVEED, for men diagnosed with hypogonadism.
Molecular and serum markers of prognosis in renal cell carcinoma have remained elusive. In large part, tumor (TNM) stage, Fuhrman grade, and patient performance status have stood the test of time as the most valuable factors in predicting patient outcome following surgery.
› Verified 5 days ago